{"prompt": "['Trelagliptin-4002', 'Page 22 of 66', 'Version 2.0', 'July 5, 2017', '6.0', 'CLINICAL STUDY DESIGN', '6.1', 'Clinical study design', '<Clinical study design>', 'This is a multi-center, randomized, open-label, parallel-group comparison study to assess the', 'reduction in treatment burden during the administration of a DPP-4 inhibitor (trelagliptin or a daily', 'DPP-4 inhibitor) for 12 weeks in patients with type 2 diabetes on diet and exercise therapy only.', 'Eligible study subjects as a result of eligibility assessment after giving informed consent will be', 'randomized to either of the study drug (trelagliptin) group or the comparative drug (daily DPP-4', 'inhibitor) group as specified in Section 8.4.', '< Dosage and Administration>', 'The study drug group: Trelagliptin 100 mg is orally administered once weekly. Trelagliptin 50', 'mg is orally administered once weekly in patients with moderate renal', 'impairment.', 'The comparative drug group: An inhibitor is orally administered at the dosage and administration in', 'the package inserts for each drug.', '<Evaluation period and visit frequency for study subjects>', 'Evaluation period: 16 weeks (Screening period: 4 weeks; treatment period: 12 weeks)', 'Number of visits: total 4 visits', 'A study subject will visit to his/her study site at the start of the screening period (Visit 1;', 'Week -4), at the start of the treatment period (Visit 2; Week 0 of the treatment period),', 'during the treatment period (Visit 3; Week 4 of the treatment period) and at the end of', 'the treatment period (Visit 4; Week 12 of the treatment period).', '<Planned number of study subjects>', 'As the number of randomized subjects:', 'The study drug (Trelagliptin) group 120 subjects', 'The comparative drug (daily DPP-4 inhibitor) group 120 subjects', '<Number of study sites>', 'Approximately 15', 'Figure 6 (a) shows an outline of the clinical study design. Refer to Appendix A for schedule of', 'examinations, observations, and evaluations.', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 23 0f 66', 'Version 2.0', 'July 5, 2017', 'Start of study', 'Informed consent procedure', 'drug', 'Eligibility tests', 'administration', 'Visit', '1', '2', '3', '4', 'Week', '-4', '0', '4', '12', 'Time window', '-29 to -1', '0', '21 to 35', '70 to 97', 'Screening period', 'Treatment', 'The study drug (Trelagliptin)', 'Trelaglipin 100 mgor50 mg/week', 'group', 'On diet and exercise therapy only', 'The comparative drug (Daily', 'Daily DPP-4inhibitor', 'DPP-4inhibitor) group', '4', '+', 'DTR-QOL', 'DTR-QOL', 'DTR-QOL', 'DTR-QOL', 'DTSQ', 'DTSQ', 'DTSQ', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 24 of 66', 'Version 2.0', 'July 5, 2017', 'Figure 6.a', 'Outline of the clinical study design', '<Outline of the clinical study>', 'Duration of treatment: 12 weeks', 'Number of visits: 4 visits', '6.2', 'Rationale for the clinical study design', '(1) Rationale for the clinical study design', 'The study was designed as an open-label, parallel-group comparative study, to assess impact', 'of trelagliptin on QOL of type 2 diabetes compared with Daily DPP-4 inhibitors. In', 'conducting this parallel-group comparative study, randomization with stratification will be', 'performed, using \"the total score for all factors (1-4) in the DTR-QOL Questionnaire (<80%', 'or 80%)\" and \"HbAlc (<8.0% or 8.0%)\" as stratification factors, for the purpose of', 'adjusting effects on the reduction level of diabetes treatment burdens in patients controlled', 'by diet/exercise therapy during Visit 1.', '(2) Rationale for the study period', 'The treatment period was designed as 12 weeks, because switch to other treatment including', 'combination therapy with other medications is recommended for a case fails to achieve the', 'therapeutic target following three-month continuous administration, as the evaluation on', 'responses to treatment with oral diabetic medications\u00b9 , and in a study which investigate', 'changes in DTR-QOL score during treatment with sodium glucose transporter 2 (SGLT2)', 'inhibitor, statistically significant increase in the score was observed at 12 weeks of treatment', 'and scores at 12 weeks and 24 weeks was comparable.', '(3) Rationale for the number of planned study subjects', 'See Section 13.3.', '6.3', 'Premature termination of entire clinical study or premature termination of', 'clinical study at a study site', '6.3.1 Premature termination criteria of entire clinical study', 'The sponsor should immediately discontinue the study when at least one of the following criteria is', 'applicable:', 'When new information or other evaluation on the safety or efficacy of the study drug becomes', 'available that shows a change in the known risk/benefit profile of the concerned compound, and', 'risks/benefits are no longer tolerable for study subject participation in the study.', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}